Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules

Takanori So* and Michael Croft*

*Correspondence: Takanori So, Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan; e-mail: tso@med.tohoku.ac.jp; Michael Croft, Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA

INTRODUCTION

The response of T lymphocytes to extrinsic stimuli has been known for many years to involve activation of phosphoinositide 3-kinase (PI3K) that results in a sustained rise in the lipid second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) produced from phosphatidylinositol (4,5)-bisphosphate (PIP2) and phosphatidylinositol (4,5)P2 translocation of a subset of proteins containing pleckstrin homology (PH) domains to the plasma membrane, such as Akt (protein kinase B) and phosphoinositide-dependent kinase 1 (PDK1). Akt activity is regulated by the binding of PIP3 or phosphatidylinositol (3,4)-bisphosphate (PIP2) to ACTA.Akt activation is mediated by the PI3K-Akt pathway, promoting clonal expansion, differentiation, and survival of effector cells and suppresses the generation of regulatory T cells. PI3K activation is tightly controlled by signals through the T cell receptor (TCR) and the co-stimulatory receptor CD28, however sustained and periodic signals from additional co-receptors are now being recognized as critical contributors to the activation of this pathway. Accumulating evidence suggests that many members of the Tumor Necrosis Factor receptor (TNFR) superfamly, TNFR2 (TNFRSF1B), OX40 (TNFRSF4), 4-1BB (TNFRSF9), HVEM (TNFRSF14), and DR3 (TNFRSF25), that are constitutive or inducible on T cells, can directly or indirectly promote activity in the PI3K-Akt pathway. We discuss recent data which suggests that ligation of one TNFR family molecule organizes a signalosome, via TNFR-associated factor (TRAF) adapter proteins in T cell membrane lipid microdomains, that results in the subsequent accumulation of highly concentrated depots of PI3K and Akt in close proximity to TCR signaling units. We propose this may be a generalizable mechanism applicable to other TNFR family molecules that will result in a quantitative contribution of these signalosomes to enhancing and sustaining PI3K and Akt activation triggered by the TCR. We also review data that other TNFR molecules, such as CD40 (TNFRSF5), RANK (TNFRSF11A), FN14 (TNFRSF12A), TACI (TNFRSF13B), BAFFR (TNFRSF13c), and NGFR (TNFRSF16), contribute to the activation of this pathway in diverse cell types through a similar ability to recruit PI3K or Akt into their signaling complexes.

Keywords: PI3K, AKT, TNFSF, TNFRSF, TRAF, signalosome

Activation of phosphoinositide 3-kinase (PI3K) and Akt (protein kinase B) is a common response triggered by a range of membrane-bound receptors on many cell types. In T lymphocytes, the PI3K-Akt pathway promotes clonal expansion, differentiation, and survival of effector cells and suppresses the generation of regulatory T cells. PI3K activation is tightly controlled by signals through the T cell receptor (TCR) and the co-stimulatory receptor CD28, however sustained and periodic signals from additional co-receptors are now being recognized as critical contributors to the activation of this pathway. Accumulating evidence suggests that many members of the Tumor Necrosis Factor receptor (TNFR) superfamly, TNFR2 (TNFRSF1B), OX40 (TNFRSF4), 4-1BB (TNFRSF9), HVEM (TNFRSF14), and DR3 (TNFRSF25), that are constitutive or inducible on T cells, can directly or indirectly promote activity in the PI3K-Akt pathway. We discuss recent data which suggests that ligation of one TNFR family molecule organizes a signalosome, via TNFR-associated factor (TRAF) adapter proteins in T cell membrane lipid microdomains, that results in the subsequent accumulation of highly concentrated depots of PI3K and Akt in close proximity to TCR signaling units. We propose this may be a generalizable mechanism applicable to other TNFR family molecules that will result in a quantitative contribution of these signalosomes to enhancing and sustaining PI3K and Akt activation triggered by the TCR. We also review data that other TNFR molecules, such as CD40 (TNFRSF5), RANK (TNFRSF11A), FN14 (TNFRSF12A), TACI (TNFRSF13B), BAFFR (TNFRSF13c), and NGFR (TNFRSF16), contribute to the activation of this pathway in diverse cell types through a similar ability to recruit PI3K or Akt into their signaling complexes.
in CD28's cytoplasmic tail (Pages et al., 1994). The overall signaling activity of CD28, including through the PI3K and Akt pathway, participates in the initial activation and division of T cells in many situations, although extensive studies have also suggested that the interaction with p85 is dispensable for many functions of CD28 in naive T cells (Fruman and Bismuth, 2009). As well as CD28 and related molecules like ICOS, many additional receptors on T cells may contribute to PI3K and Akt activity. Sustained and periodic signaling from these receptors over time is increasingly being recognized as vital for continued T cell differentiation and survival, further suppression of Treg development, the generation of memory, and the reactivation of memory T cells. Members of the tumor necrosis factor receptor (TNFR) superfamily constitute many of these receptors (Croft, 2003, 2009; Watts, 2005; So et al., 2006). Although all of the TNFR family members discussed in this review are strong activators of NF-κB, and NF-κB certainly plays a role in many of the functional consequences of triggering these receptors, increasing evidence suggests that their ability to also target PI3K and Akt may be integral to their function. In T cells, these receptors include TNFR2 (TNFRSF1B), OX40 (TNFRSF4), 4-1BB (TNFRSF9), HVEM (TNFRSF14), and DR3 (TNFRSF25), which are either constitutively expressed or induced after activation (Figure 1). There are several other TNFR molecules that control T cell function, such as CD27 (TNFRSF7), CD30 (TNFRSF8), and GITR (TNFRSF18), that have yet to be described to promote activation of PI3K or Akt, however it is highly likely that they also have the ability to target this pathway (Figure 1). This review summarizes recent findings on the potential importance of TNFR family signaling in stimulating the PI3K-Akt pathway in T cells as well as in other cell types, and

**FIGURE 1** | Tumor necrosis factor receptor family molecules that possibly activate the PI3K-Akt pathway in T cells. Molecular interactions between TNF receptor superfamily (TNFRSF) members and TNF ligand superfamily (TNFSF) members: TNFR2 (TNFRSF1B) and TNF (TNFSF2) or LTα (TNFSF1); OX40 (TNFRSF4) and OX40L (TNFSF4); CD27 (TNFRSF7) and CD70 (TNFSF7); CD30 (TNFRSF8) and CD30L (TNFSF8); 4-1BB (TNFRSF9) and 4-1BBL (TNFSF9); HVEM (TNFRSF14) and LIGHT (TNFSF14); GITR (TNFRSF18) and GITRL (TNFSF18); DR3 (TNFRSF25) and TL1A (TNFSF15). Interactions between TNFR-associated factors (TRAFs) and TNFRSF molecules are indicated in the inner circle. CD27, CD30, and GITR have yet to be described to promote activation of PI3K or Akt, but this is likely given their overlapping TRAF-binding capacity.
discusses the likely mechanism of how TNFR family molecules organize signalosomes on the membrane to sustain lipid signaling. The initial sections will present a brief overview of reported activities of TNFR family members on T cells that have been described to augment PI3K or Akt activity. We will then discuss the potential molecular connections that allow these molecules to link to PI3K or Akt, and lastly review PI3K and Akt related activation by other TNFR family members in non-T cells.

**REGULATION OF T CELL CO-SIGNALING BY TNFRSF MEMBERS: TNFR2, OX40, 4-1BB, HVEM, AND DR3**

**TNFR2 (TNFRSF1B)**

TNFR2 is mainly expressed in cells of the immune system including T cells. The ligand TNF (TNFSF2) is produced by activated macrophages, T cells, and many other cell types, and exists as a transmembrane trimer whose proteolysis also leads to a soluble form. TNFR2 is more efficiently triggered by transmembrane TNF than by soluble TNF (Grell et al., 1995; Faustman and Davis, 2010). TNFR2 is constitutively expressed on T cells and increases its expression after T cell activation. Interaction of TNF with TNFR2 is co-stimulatory to TCR-mediated T cell activation and effector T cell differentiation (Kim and Teh, 2001, 2004; Aspalter et al., 2003; Kim et al., 2006) and TNFR2-deficient T cells possess a defect in survival during the early phase of clonal expansion that correlates with a defect in survivin, Bcl-2, and Bcl-2XL expression (Kim and Teh, 2004; Kim et al., 2006). Importantly, TNFR2 was found to sustain Akt activity in T cells stimulated through the TCR and CD28. Given the described activities of PI3K-Akt in promoting expression of the aforementioned anti-apoptotic and cell cycle related molecules in various cell types including T cells, this data suggested that TNFR2 triggered Akt signaling may have participated in regulating expansion and survival of these effector-type T cells (Kim and Teh, 2004). The differentiation of effector T cells from a naïve population is counter to the differentiation of regulatory T cells (iTreg), and activation of PI3K and Akt has been shown to block induction of Foxp3 and iTreg development (Haxhinasto et al., 2008; Sauer et al., 2008). In line with this, neutralization of TNF has also recently been found to enhance development of iTreg cells (Zhang et al., 2013). TGF-β-induced Smad3 phosphorylation directs transcription of Foxp3 and formation of iTreg, and phosphorylation of Akt through TNF-TNFR2 interaction was described to facilitate Akt-Smad3 interaction and suppress Foxp3 expression, potentially explaining in part why TNF would block iTreg differentiation (Zhang et al., 2013).

Substantiating that Akt is a general target of TNF signaling, Akt phosphorylation has also been shown to be enhanced through TNFR1 and/or TNFR2 in various cell types, such as HEK293 cells (Ozes et al., 1999), HeLa cells (Ozes et al., 1999; Pastorino et al., 1999), HepG2 cells (Reddy et al., 2000), U937 cells (Reddy et al., 2000), endothelial cells (Zhang et al., 2003a), fibroblasts (Hanna et al., 1999; Zhang et al., 2001), myocytes (Hiraoka et al., 2001), cortical neurons (Marchetti et al., 2004), and hepatocytes (Osawa et al., 2001).

**OX40 (TNFRSF4)**

OX40 is induced on activated T cells while its ligand, OX40L (TNFSF4), is inducible on professional antigen-presenting cells (APCs). OX40-OX40L interactions positively regulate conventional T cell responses and can negatively affect iTreg differentiation (So et al., 2008; Croft et al., 2009; Croft, 2010; Ishii et al., 2010). OX40 functions later than CD28, and potentially later than TNFR2, providing signals to promote continued division and survival, and hence clonal expansion of effector and memory T cells (Gramaglia et al., 2000). OX40 signaling was shown to augment and sustain PI3K-Akt activity when antigen was presented to T cells, again correlating with its ability to promote continued expression of molecules that control cell cycle progression as well as anti-apoptotic Bcl-2 family members (Rogers et al., 2001; Song et al., 2004, 2005). Importantly, a dominant-negative version of Akt reproduced many of the defects associated with a lack of OX40 expression, and introduction of a constitutively active version of Akt into T cells that lacked OX40 almost fully reversed the defect in clonal expansion and survival exhibited by these T cells (Rogers et al., 2001; Song et al., 2004, 2005). OX40 signaling also antagonizes the differentiation of Foxp3+ or IL-10+ iTreg (Ito et al., 2006; So and Croft, 2007; Vu et al., 2007). No formal proof has been provided that OX40 inhibition of Foxp3 and iTreg development is mediated in part by Akt activation, but again this is likely.

**4-1BB (TNFRSF9)**

4-1BB is another inducible molecule on activated T cells that can be triggered by 4-1BBL (TNFSF9) expressed on activated APCs (So et al., 2008; Snell et al., 2011; Vinay and Kwon, 2012). 4-1BB ligation can again promote T cell clonal expansion, differentiation, and expression of cytokines, and can enhance the survival of effector and memory T cells through upregulation of Bcl-2. 4-1BB signaling also has the ability to inhibit TGF-β-driven conversion of naïve CD4+ T cells into iTreg either through direct activity or indirectly via upregulation of IFNγ production (Madireddi et al., 2012). 4-1BB was found to promote phosphorylation of Akt in T cells, and proliferative responses mediated by 4-1BB were blocked by a PI3K inhibitor, coincident with suppressing cyclin expression and promoting the cell cycle regulatory molecules p27Kip1 (Lee et al., 2002, 2003). Some studies suggested that 4-1BB induced the anti-apoptotic Bcl-2 family molecules, Bcl-2 and Bcl-XL, in murine T cells in a PI3K-Akt independent manner (Lee et al., 2002, 2003). However, suppression of apoptosis and induction of c-FLIPshort and Bcl-XL by 4-1BB in human peripheral blood T cells was blocked by targeting PI3K or Akt (Starck et al., 2005).

**HVEM (TNFRSF14)**

HVEM can interact with a number of different ligands, however its primary activating ligand in the TNF family is LIGHT (TNFSF14). HVEM is widely expressed on many cell types, including being constitutive on T cells. LIGHT in contrast is inducible on T cells as well as certain APCs such as DC and B cells upon activation (Steinberg et al., 2011; Ware and Sedy, 2011). Ligation of HVEM by LIGHT provides stimulatory signals that additionally can impact activation, differentiation, or survival of T cells. In line with HVEM controlling Akt activation at later stages of T cell responses, HVEM-deficient T cells were shown to display reduced Akt activity at the peak of the effector response that correlated with defective expression of Bcl-2 and reduced T cell survival.
Furthermore, the defect in T cell survival was rescued by ectopic expression of an active form of Akt (Soroosh et al., 2011).

Substantiating Akt as a downstream target of HVEM, the ability of LIGHT to induce macrophage migration and vascular smooth muscle cell proliferation also correlated with activation of PI3K and Akt (Wei et al., 2006), and LIGHT was found to promote PI3K-Akt phosphorylation in osteoclast precursor cells, supporting osteoclast differentiation (Hemingway et al., 2013).

**DR3 (TNFRSF25)**

DR3 is constitutively expressed by T cells and is upregulated following T cell activation, while TL1A (TNFSF15), the ligand for DR3, is induced in APCs (Meylan et al., 2011). Interaction of TL1A with DR3 also provides costimulatory signals to T cells in concert with antigen/TCR signaling and this can contribute to enhanced production of pro-inflammatory cytokines, and increased clonal expansion and differentiation of T cells. Although no studies have been conducted as yet on conventional T cells, ligation of DR3 was shown to promote Treg proliferation that was blocked by an Akt inhibitor (Schreiber et al., 2010). Stimulation of DR3-expressing human acute monocytic leukemia THP-1 cells with TL1A, or anti-DR3 antibodies, also induced phosphorylation of Akt concomitant with upregulation of expression of βι-г3, an extracellular matrix protein. This was blocked by an inhibitor of PI3K and inhibitors of PKC, suggesting that PKC activation by DR3 may be involved in PI3K-Akt activation via this receptor in this cell type (Lee et al., 2010). Lastly, E-selectin (CD62E) has been suggested to be an alternate ligand for DR3, and E-selectin was found to activate the PI3K-Akt pathway via DR3 in HT29 colon carcinoma cells (Porquet et al., 2011).

**TNF RECEPTOR OLIGOMERIZATION, MEMBRANE LIPID MICRODOMAINS, AND THE T CELL TNFR SIGNALOSOME**

Although the studies described above show that TNFR2, OX40, 4-1BB, HVEM, and DR3 can enhance PI3K and Akt activation in T cells or other cell types, a primary question is whether this is a direct activity, or indirect through modulating or enhancing signaling through other non-TNFR molecules including the TCR or CD28. Moreover, as these TNFR molecules do not have obvious PI3K-binding motifs, similar to the pYMMN motif of CD28, it is not clear how they would directly link to PI3K or Akt or how the connection with the lipid mediators is facilitated.

TNF family ligands share the TNF homology domain (THD), which binds to cysteine-rich domains (CRDs) of the TNF family receptors. TNF ligands are synthesized as either membrane-bound or soluble trimeric proteins. Many biochemical and functional studies show that the transmembrane ligands can robustly activate receptors whereas the soluble trimeric ligands differ in their ability to be activating molecules. Some TNFR molecules, such as TNFR1 and CD40, are thought to be pre-clustered at the cell surface in the absence of their cognate TNF ligand (Chan, 2007), which likely aids their ability to respond to the soluble ligand. This is exemplified by TNF, which is highly active in soluble form when recognizing TNFR1. In contrast, studies of trimers of molecules such as OX40L and 4-1BB have suggested they do not have functional effects when soluble, implying their receptors are not pre-assembled into clusters. However, artificially generated oligomerized versions of soluble trimeric ligands, including OX40L, 4-1BBL, and GITRL work as highly efficient agonists in T cells and other cell types (Haswell et al., 2001; Zhang, 2004; Stone et al., 2006; Muller et al., 2008; Zhou et al., 2008; Wyzgol et al., 2009). Other variants on this theme are molecules like APRIL whose soluble form can be oligomerized naturally through interaction with polysaccharide side chains of heparin sulfate proteoglycans, allowing effective signals through its receptors TACI or BCMA (Ingold et al., 2005; Kimberley et al., 2009); or BAFF that also binds to TACI, and is unable to activate this receptor as a single trimer, but can assemble as an ordered structure comprising 20 trimers (60-mer) and then gains the ability to be a strong TACI agonist (Liu et al., 2002; Bossen et al., 2008). In sum, these results suggest that oligomerization of most TNFR molecules, beyond the basic trimeric complex that would be formed after ligation of a single trimeric ligand, is a prerequisite for efficient recruitment and activation of signaling moieties.

All TNFR family molecules also promote intracellular kinase activation at least in part through adaptor proteins called TNFR-associated factors (TRAFs). For example, TNFR2 has the potential ability to recruit and/or directly bind TRAFs 1 and 2 (Rothe et al., 1994); OX40: TRAFs 1, 2, 3, and 5 (Kawamata et al., 1998); 4-1BB: TRAFs 1, 2, and 3 (Jang et al., 1998); HVEM: TRAFs 1, 2, 3, and 5 (Marsters et al., 1997); and DR3: TRAF2 (Chinnaiyan et al., 1996). TRAF proteins already can exist as trimers in the cytosol before binding to the cytoplasmic tails of TNFR receptors (Park et al., 1999), suggesting that oligomerization of the receptors will then additionally result in oligomerized scaffolds of at least one, but more likely multiple, TRAF molecules.

Another facet that might be important to the ability of TNFR family molecules to link to PI3K and Akt directly is the regulated movement of TNFR oligomers into detergent-insoluble cholesterol- and sphingolipid-rich plasma membrane microdomains (DIM or lipid rafts). Here the spatiotemporal regulation of protein–protein interactions and dynamic protein networks may orchestrate to allow any biological outcome (Dykstra et al., 2003; Viola and Gupta, 2007). DIM are estimated as <20 nm diameter in a living cell (Eggeling et al., 2009), indicating that molecules that translocate into DIM are likely condensed into a small area. Although not investigated for many TNFR molecules to date, particularly in T cells, several members of the family have been visualized to concentrate in DIM after stimulation by their ligands including OX40 (So et al., 2011a,b) and 4-1BB (Nam et al., 2005). Therefore, translocation into lipid-rich microdomains might be a common and important feature of the TNFR family. Moreover, TRAF2 can interact with Filamin-A, which functions as a scaffold for DIM formation (Leonardi et al., 2000; Arron et al., 2002), and with Caveolin-1, which is a component of DIM (Feng et al., 2001), suggesting that recruitment of this molecule might promote or maintain localization of TNFR molecules in these lipid-rich areas. TRAF2 binding is shared by all TNFR family molecules that have been described to co-stimulate T cells (Figure 1), including those shown to date to promote PI3K and Akt activation (see above), implying TRAF2 may be a critical link to PI3K and/or Akt. Perhaps of equal significance, PIP3 is enriched and constitutively associated with DIM, and at least...
in T cells, a proportion of total cellular PI3K and PDK1 are constitutively associated with detergent-insoluble fractions (Pike and Casey, 1996; Dykstra et al., 2003; So et al., 2011a). Therefore, it is reasonable to suggest that these lipid-rich microdomains are likely to play a critical role in triggering PI3K-Akt signaling by facilitating the localization of oligomerized TNFR and TRAF molecules with PI3K, PIp2, and PDK1 (Lasserre et al., 2008). This would enhance the likelihood of PIp3 production, and membrane recruitment and phosphorylation of Akt, assuming PI3K can be activated.

Only studies of one molecule to date have shown a direct link of a TNFR family molecule to PI3K and Akt in T cells. However, there is strong rationale that the findings will be generalizable. We clearly demonstrated in several studies that OX40 signaling strongly synergizes with antigen signals to augment Akt activity in recently activated or effector T cells (Song et al., 2004; So et al., 2011a,b). After interaction of OX40 with transmembrane OX40L, OX40 moved into DIM and immunoprecipitation experiments revealed that it organized a signalosome containing many molecules including TRAF2, the I KK complex, and PKC0 and the CARMA1-BCL10-MALT1 complex, that regulate NF-κB1 activation, and also including p85 PI3K and Akt (So et al., 2011a,b). The formation of this complete OX40 signalosome in T cells was dependent on TRAF2 and on translocation of OX40 into DIM, but independent of antigen/TCR stimulation (So et al., 2011a,b). Moreover, in the absence of TRAF2 or by disrupting DIM, OX40 could not complex with either PI3K or Akt. Interestingly, OX40 was unable to induce significant cellular phosphorylation of PI3K, PIp3 accumulation, or Akt activation, unless antigen was presented to the T cells, even though antigen/ TCR recognition had no obvious impact on recruitment of PI3K or Akt to the OX40 signalosome. The explanation for this was not clear, but we only found a moderate amount of PDK1 associated with the OX40 complex suggesting that this might in part contribute to the inability of OX40 ligation in isolation to lead to phosphorylation of Akt, and why antigen recognition was essential. However, more recent data have shown that OX40 associates with an E3 ligase that appears to limit its ability to activate Akt in T cells (Croft, unpublished). This then suggests that OX40 does possess the capacity to activate Akt independently of other receptors, but regulatory elements may keep this ability in check in T cells providing control over this aspect of OX40 biology to the TCR. Importantly, these data then imply that OX40 functions in T cells by quantitatively enhancing the amount of PI3K and Akt that is available to be activated in the T cells, even though antigen/TCR signaling had no obvious influence in DIM of T cells essentially offer functional hot spots of higher ordered oligomerized TNFR-ligand modules that are organized in lipid-rich microdomain environment. We hypothesize that the higher ordered oligomerized TNFR-ligand modules that are organized in DIM of T cells essentially offer functional hot spots of concentrated PI3K and Akt in the vicinity of the TCR/CD28 signalosome (Figure 2). These data also highlight that TRAF adaptors are likely to play critical roles in linking the TNFR family to PI3K and Akt in T cells. Our studies show that TRAF2 is important for OX40 to recruit both PI3K and Akt into its signaling complex, but whether TRAF2 directly binds one or both molecules is not yet clear. Other TRAFs, particularly TRAF6, may be also critical as described below in non-T cells, although how much this might vary from a T cell to another cell type is also not clear.

**REGULATION OF PI3K AND AKT BY TNFRSF MEMBERS IN NON-T CELLS: CD40, RANK, FN14, TACI/BAFFR, AND NGFR**

**CD40 (TNFRSF5)**

Signaling through CD40 after ligation by CD40L (TNFSF5) is important for promoting the activation, division, and maturation of APCs, and isootype switching of B cells (Graham et al., 2010; Gommerman and Summers deLuca, 2011). CD40 can directly bind to TRAFs 1, 2, 3, 5, and 6 (Pullen et al., 1998) and CD40 engagement leads minimally to translocation of CD40, TRAF2, TRAF3, and TRAF6 into DIM where CD40 activates downstream signaling cascades (Hostager et al., 2000; Vidalain et al., 2000; Arron et al., 2001). Cross-linking CD40 has been found to activate PI3K in the Daudi human B lymphoblastoid line (Ren et al., 1994), and promote Akt phosphorylation, downregulation of p27kip1, and upregulation of Bcl-xl in primary murine B cells that was blocked by a PI3K inhibitor (Andjelic et al., 2000). CD40-induced proliferation and survival of B cells deficient in a negative regulatory adaptor molecule was also suppressed by introduction of dominant-negative Akt (Aiba et al., 2006). After triggering CD40 on murine bone marrow-derived DCs, p85 PI3K was furthermore found to be recruited to CD40 correlating with enhanced Akt activation (Arron et al., 2001). Similarly, CD40L induced Akt phosphorylation and survival in human monocyte-derived DCs that was blocked with a PI3K inhibitor (Yu et al., 2004). In other cells, stimulation of CD40 on human microvascular endothelial cells also induced PI3K and Akt phosphorylation, concomitant with an increase in cell survival and proliferation, and these functional activities were suppressed by PI3K inhibitors and a dominant-negative version of Akt (Deregibus et al., 2003).

Although the adaptors required for CD40 to connect to PI3K and Akt have not been investigated in every situation, several pieces of evidence suggest TRAF6 and/or TRAF2 are crucial. For example, CD40 was shown to block apoptosis induced by the Fas death receptor in a PI3K and Akt dependent manner, and this was abrogated in B cells that were deficient in TRAF6 (Benson et al., 2006). A CD40 signalosome containing TRAF2, TRAF6, and p85 PI3K was also visualized in endothelial cells (Deregibus et al., 2003) and a signalosome of TRAF6 and PI3K in DCs (Arron et al., 2001). Lastly, fibroblasts lacking TRAF2 or TRAF6 displayed impaired Akt phosphorylation that was triggered by CD40 engagement (Davies et al., 2005).

**RANK (TNFRSF11A)**

RANK interactions with RANKL (TNFSF11) regulate bone remodeling, lymph node formation, establishment of the thymic microenvironment, and mammary gland development during pregnancy (Leibbrandt and Penninger, 2008). RANK has the potential to recruit TRAFs 1, 2, 3, 5, and 6 (Wong et al., 1998; Darnay et al., 1999) and triggering of RANK with RANKL has been shown to promote activation of the PI3K-Akt pathway in osteoclasts and DCs. Similar to CD40, RANK was visualized to induce a signalosome containing TRAF6 and p85 PI3K in these cell types. PP1, an inhibitor for Src family kinases, inhibited Akt phosphorylation mediated by RANK, indicating that c-Src is an upstream regulator of PI3K. In accordance, the kinase activity of c-Src was upregulated in the RANK signalosome and RANK was.
So and Croft

TNFR family control of PI3K and Akt

FIGURE 2 | Model of synergy between TCR/CD28 and TNFR signalosomes for activation of the PI3K-Akt pathway in T cells. T cells are activated firstly by recognition of antigen by the T cell receptor (TCR)/CD3 complex when it is displayed by the major histocompatibility complex (MHC) on antigen-presenting cells (APCs). The second co-stimulatory signal is delivered through CD28 by interaction with its ligands CD80 and/or CD86. These combined signals can activate phosphoinositide 3-kinase (PI3K), which leads to conversion of PIP$_2$ into PIP$_3$ at the plasma membrane. The pleckstrin homology (PH) domain containing proteins, Akt (protein kinase B) and phosphoinositide-dependent kinase 1 (PDK1), are recruited to the membrane PIP$_3$, and then Akt is phosphorylated by PDK1 and by the mammalian target of rapamycin complex 2 (mTORC2). This promotes translocation of Akt from membrane to cytosol, thereby allowing regulation of downstream pathways through phosphorylation of target molecules, such as glycogen synthase kinase $\beta$ (GSK3$\beta$), forkhead box O (Foxo), and I$\kappa$B kinase (IKK). Akt phosphorylates and inactivates two negative regulators of mTORC1, tuberous sclerosis complex 2 (TSC2) and proline-rich Akt substrate of 40 kDa (PRAS40), which results in activation of mTORC1. Akt contributes to NF-$\kappa$B activation through phosphorylation of IKK and interaction with protein kinase C $\theta$ (PKC$\theta$) or caspase-recruitment domain (CARD)-membrane-associated guanylate kinase (MAGUK) protein 1 (CARMA1). After recognition of trimeric TNF ligand superfamily (TNFSF) molecules on APCs, TNF receptor superfamily (TNFRSF) molecules on T cells are trimerized and oligomerized and recruit trimeric TNFR-associated factors (TRAFs) to their cytoplasmic TRAF-binding motifs. The TNFSF-TNFRSF complex then translocates into detergent-insoluble membrane lipid microdomains (DIM). The TNFRSF-TRAF superclusters recruit and allow the efficient accumulation of PI3K and Akt in concentrated depots in close proximity to the TCR/CD28 signalosome, which results in a quantitative contribution of TNFR signalosomes to enhancing and sustaining PI3K and Akt activation triggered by the TCR/CD28 signalosome. The TNFR signalosomes also can promote activation of NF-$\kappa$B irrespective of TCR/CD28 signaling. Red lines show activating signals, blue lines show inhibitory signals.

found unable to activate Akt without the enzymatic activity of c-Src (Wong et al., 1999; Arron et al., 2001; Xing et al., 2001). TRAF6 again may be critical for the ability of RANK to target the PI3K-Akt pathway, and certain elements might also limit Akt activation. Upon stimulation of RANK in the RAW264.7 monocyte/macrophage cell line, phosphorylation of PI3K and Akt was upregulated and this was further amplified by introduction of dominant-negative SHP-1. TRAF6 was found to interact with RANK and SHP-1, and SHP-1 antagonized the association between RANK and TRAF6 (Zhang et al., 2003b). Similar to other TNFR molecules, RANK may also function in the context of DIM. After engagement by RANKL in osteoclasts, TRAF6 was shown to translocate into DIM where c-Src is constitutively resident, and disruption of DIM reduced Akt activation and concomitantly blocked osteoclast differentiation, survival, and bone resorption activity (Ha et al., 2003).
FN14 (TNFRSF12A)

FN14 is another TNFR molecule. It is expressed on epithelial cells, endothelial cells, and other non-hematopoietic cells and engages TWEAK (TNFSF12) and promotes a number of differentiation activities depending on the cell type. Stimulation of FN14 on mouse osteoblastic MC3T3-E1 cells induced Akt phosphorylation and RANTES production in a PI3K-dependent manner (Ando et al., 2006). TWEAK also promoted expression of ICAM-1 and VCAM-1 on human gingival fibroblasts that was blocked with an inhibitor of PI3K (Hosokawa et al., 2006), and Akt phosphorylation and matrix metalloprotease-9 (MMP-9) expression in mouse C2C12 myotubes was suppressed by targeting PI3K or introducing a dominant-negative version of Akt (Kumar et al., 2009). Similar results were also reported with TWEAK activation of FN14 on: renal tubular epithelium cells where PI3K inhibitors prevented upregulation of cyclin D1 and cell proliferation (Sanz et al., 2009); cardiomyocytes where FN14-mediated proliferation was also blocked by interfering with PI3K activity (Novoyatleva et al., 2010); and human gingival fibroblasts where the PI3K-Akt pathway contributed to induction of CCL20 (Hosokawa et al., 2012). FN14 has the potential to directly recruit and bind TRAFs 1, 2, 3, and 5 (Brown et al., 2003) but no studies to date have attempted to link a specific TRAF to the ability of FN14 to phosphorylate and activate PI3K or Akt.

TACI (TNFRSF13B)/BAFFR (TNFRSF13C)/BCMA (TNFRSF17)

TACI, BAFFR, and BCMA are mainly expressed on B cells and play critical roles in survival of B cells at distinct stages of development by engaging APRIL (TNFSF13) and/or BAFF (TNFSF13B) (Rickert et al., 2011). BAFFR can activate the PI3K-Akt pathway in mature B cells (Patke et al., 2006; Otipoby et al., 2008; Woodland et al., 2008) and BAFF-mediated proliferative and survival responses were defective in B cells lacking p110δ PI3K (Henley et al., 2008). PKCδ was found to interact and directly phosphorylate Akt on serine 473 after ligation of BAFFR, with Akt phosphorylation being greatly reduced in PKCδ-deficient B cells (Patke et al., 2006). Folicular lymphoma B cells were additionally found to respond to APRIL–TACI stimulation by phosphorylating p85 PI3K, Akt, mTOR, 4E-BP1, and p70S6K, and PI3K inhibitors blocked these APRIL-induced activities and cellular proliferation (Gupta et al., 2009).

Stimulation of human myeloma cells expressing TACI, BAFFR, and BCMA with BAFF or APRIL has also been shown to activate the PI3K-Akt pathway concomitant with protection against apoptosis (Moreaux et al., 2004); and lastly human adipose-derived stem cells additionally phosphorylated Akt after exposure to APRIL or BAFF (Zonca et al., 2012). Similar to other TNFR family members, TACI, BAFFR, and BCMA may directly recruit and bind TRAFs 2, 5, and 6 (Xia et al., 2000), TRAFs 2 and 3 (Xu and Shu, 2002), and TRAFs 1, 2, 3, 5, and 6 (Hatzoglou et al., 2000; Shu and Johnson, 2000), respectively, suggesting that TRAF2 and/or 6 may again mediate PI3K-Akt signaling, although no studies have addressed this as yet.

NGFR (TNFRSF16, p75NTR)

Lastly, NGFR that is mainly expressed on neurons and glia during development of the central nervous system, and is induced after many types of nervous system injury, also appears to utilize PI3K and Akt for certain activities. NGFR only binds neurotrophins [nerve growth factor (NGF); brain-derived neurotrophic factor (BDNF); and neurotrophin-3 and -4 (NT-3 and -4)]. NGFR may primarily work as a co-receptor and cooperates with the Trk receptor tyrosine kinase family (Trk-A, -B, and -C), Sortilin-family receptors, and Nogo receptor/Lingo-1 (Ibanez and Simi, 2012). Many studies (e.g., refs Soltolff et al., 1992; Yao and Cooper, 1995; Jackson et al., 1996; Vaillant et al., 1999; Takano et al., 2000) have shown that NGF activates PI3K and induces PI3P production, and that the Akt pathway works as a key regulator of neurotrophin-induced neuronal survival. NGFR signaling is initiated in caveolae, which are a special type of DIM and serve as signaling platforms (Bilderback et al., 1999; Huang et al., 1999), but the contribution of individual TRAF molecules to activation of PI3K and Akt has not yet been reported. NGFR can directly bind TRAFs 2 and 6 (Khursigara et al., 1999; Ye et al., 1999), and TRAF6 recruitment has been suggested to be essential for signal transduction activity (Vilar et al., 2009), again implying this receptor may connect to the PI3K-Akt pathway via similar TRAF adaptors as other members of the TNFR family.

CONCLUSION

In conclusion, many stimulatory TNFR family members have been reported to augment PI3K and Akt activation in diverse cell types, suggesting that this pathway can be a major contributor to the functional effects mediated by these molecules. After interaction with their transmembrane, and in some cases soluble, TNF family ligands, TNFR molecules oligomerize and organize signalomes in membrane lipid microdomains. The cytoplasmic domain of TNFR family members does not have the consensus motif that can directly bind PI3K. Rather, TNFR molecules bind to overlapping but distinct subsets of TRAF adaptor proteins, and these adaptors initiate many of the signals delivered by the receptors. Increasing evidence suggests that TRAF2 and TRAF6 are required for recruitment of PI3K or Akt into TNFR signalomes, but whether these TRAF molecules directly bind to PI3K or Akt is not clear. In overexpression studies, and in MEFs stimulated with IGF-1 or IL-1, TRAF6 was precipitated with Akt, and furthermore TRAF6 induced K63-linked ubiquitination and membrane localization of Akt (Yang et al., 2009). Thus it is possible that this is also a primary activity when TRAF6 is recruited to a TNFR molecule. However, not all TNFR family members that have been reported to promote PI3K and Akt activation appear to bind or recruit TRAF6, but they may all interact with TRAF2. This implies that TRAF2 could be the crucial adaptor in some cases, but whether TRAF2 possesses the same activity as TRAF6 in being able to complex with, and ubiquitinate, Akt is presently unknown.

In T cells, TNFR family molecules are crucial for clonal expansion and survival, and for the generation of T cell memory, and increasing evidence suggests these functional effects are in part mediated by enhancing antigen-initiated PI3K and Akt activity. Some TNFR family molecules in non-T cells appear to have the capacity to activate PI3K and Akt without signaling from other receptors, suggesting they may directly phosphorylate PI3K and/or recruit other kinases that can perform this function, and they
may also recruit kinases such as PKD1 that phosphorylate Akt. In contrast, most evidence suggests that in T cells the ability of TNFR molecules to promote phosphorylation of PI3K and Akt is restricted unless the TCR recognizes antigen. This makes sense as T cells are governed by many checkpoints that limit their response in an attempt to control autoreactivity. Thus, it is likely that the higher-order TNFR-TRAF superclusters induced within lipid-rich microdomains of T cells then allow the efficient accumulation of PI3K and Akt in concentrated depots in close proximity to the TCR signalosome, and the function of this would be to either relieve a molecular checkpoint that limits Akt phosphorylation, or would be to simply provide more molecules of Akt available to the TCR. Further work in this area is required to fully understand the nature of TNFR signalosomes and how they may differ from molecule to molecule and in T cells versus other cell types.

ACKNOWLEDGMENTS

Michael Croft is supported by NIH grants CA91837, AI49453, AI089624, AI010095, and AI070535.

REFERENCES

Aiba, Y., Yamazaki, T., Okada, T., Gotoh, K., Sanjo, H., Ogata, M., et al. (2006). BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 24, 259–268. doi:10.1016/j.immuni.2006.01.002

Andjelic, S., Hsia, C., Suzuki, H., Kadowaki, T., Koyasu, S., and Liu, H. C. (2000). Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways. J. Immunol. 165, 3860–3867.

Ando, T., Ichikawa, J., Wako, M., Hatayashiki, K., Watanabe, Y., Sakuma, M., et al. (2006). TWEAK/Fn14 interaction regulates RANTES production, RIMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res. Ther. 8, R146. doi:10.1186/ar8288

Arron, J. R., Pevner-Junger, Y., Walsh, M. C., Kobayashi, T., and Choi, Y. Y. (2002). Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor-activated B cell signal transduction. J. Exp. Med. 196, 923–934. doi:10.1084/jem.20020774

Arron, J. R., Vologodskaia, S., Liu, B. R., Naramura, M., Kim, N., Gu, H., Sushika, K., Watanabe, Y., Sakuma, M., et al. (2001). A positive regulatory role for Cbl family proteins in tumor necrosis factor-related apoptosis inducer (TRAIL) signaling. Blood 923–934. doi:10.1182/jem.20020774

Bilderback, T. R., Gazala, V. R., Lisanti, M. P., and Dobrowolski, R. T. (1999). Caveolin interacts with

Trk A and p75(NTR) and regulates neurotrophin signaling pathways. J. Biol. Chem. 274, 257–263. doi:10.1074/jbc.274.1.257

Bosson, C., Cacherio, T. G., Tardivel, A., Ingold, K., Willen, L., Dobles, M., et al. (2008). TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111, 1004–1012. doi:10.1182/blood-2007-09-110874

Brown, S. A., Richards, C. M., Hanscomb, H. N., Feng, S. L., and Winkles, J. A. (2003). The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J. 371, 395–403. doi:10.1042/BJ20021730

Chan, F. K. (2007). Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37, 101–107. doi:10.1016/j.cyto.2007.03.005

Chinnaiyan, A. M., O’Rourke, K., Yu, G. L., Lyons, R. H., Garg, M., Duan, D. R., et al. (1996). Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD40. J. Cell Biol. 120601.141021

Davies, C. C., Mak, T. W., Young, L. S., and Ellopolous, A. G. (2005). TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol. Cell. Biol. 25, 9086–9019. doi:10.1128/MCB.25.22.9086–9019.2005

Deregibus, M. C., Buttiglieri, S., Russo, S., Bussolati, B., and Camussi, G. (2003). CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J. Biol. Chem. 278, 18008–18014. doi:10.1074/jbc.M300711200

Dykstra, M., Cherukuri, A., Sohn, H. W., Teng, S. J., and Pierce, S. K. (2003). Location is everything: lipid rafts and immune cell signaling. Annu. Rev. Immunol. 21, 457–481. doi:10.1146/annurev.immunol.21.120601.141021

Eggeling, C., Ringemann, C., Medda, R., Schwarzmann, G., Sandhoff, K., Polyakova, S., et al. (2009). Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457, 1159–1162. doi:10.1038/nature07596

Faustman, D., and Davis, M. (2010). TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482–493. doi:10.1038/nrd3030

Feng, X., Gaeta, M. L., Madge, L. A., Yang, J. H., Bradley, J. R., and Pober, J. S. (2001). Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J. Biol. Chem. 276, 8341–8349. doi:10.1074/jbc.M007116200

Finlay, D., and Cantrell, D. (2011). The coordination of T-cell function by serine/threonine kinases. Cold Spring Harb. Perspect. Biol. 3, a00261. doi:10.1101/cshperspect.a00261

Fruman, D. A., and Bischun, G. (2009). Fine tuning the immune response with PI3K. Immunol. Rev. 228, 253–272. doi:10.1111/j.1600-065X.2008.00756.x

Gommernner, J. L., and Summers deLuca, L. (2011). LTbetaR and CD40: working together in dendritic cells to optimize immune responses. Immunol. Rev. 244, 85–98. doi:10.1111/j.1600-065X.2011.01056.x

Graham, J. P., Aricipowksi, K. M., and Bishop, G. A. (2010). Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunology 127, 224–248. doi:10.1111/j.1600-065X.2010.00932.x

Gramaglia, L., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N., and Croft, M. (2000). The CD40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165, 3043–3050.

Grell, M., Dziun, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., et al. (1995). The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793–802. doi:10.1016/0092-8674(95)00192-2

Gupta, M., Dillon, S. R., Ziesemer, S. C., Feldman, A. L., Witzig, T. E., Ansell, S. M., et al. (2009). A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 113, 5206–5216. doi:10.1182/blood-2008-09-179762

Ha, H., Kovak, H. R., Lee, S. K., Na, D. S., Rudd, C. E., Lee, Z. H., et al. (2003). Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. J. Biol. Chem. 278, 18573–18580. doi:10.1074/jbc.M212626200
In interleukin 1beta-stimulated human gingival fibroblasts. 
Hum. Immunol. 73, 470–473. doi:10.1016/j.humimm.2012.02.021

Hostager, B. S., Catlett, I. M., and Bishop, G. A. (2000). Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J. Biol. Chem. 275, 13592–13598. doi:10.1074/jbc.M095201209

Huang, C. S., Zhou, J., Feng, A. K., Lynch, C. C., Klumperman, I., Deardorn, S. I., et al. (1999). Nerve growth factor signaling in caveole-like domains at the plasma membrane. J. Biol. Chem. 274, 36767–36774. doi:10.1074/jbc.M5137077

Huang, Y. H., and Sauer, K. (2010). Lipid signaling in T-cell development and function. Cold Spring Harb. Perspect. Biol. 2, a002428. doi:10.1101/chperspect.a002428

Ibanez, C. F., and Simi, A. (2012). p75 Neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci. 35, 431–440. doi:10.1016/j.tins.2012.03.007

Ingle, K., Zamsteg, A., Tardivel, A., Huard, B., Steiner, Q. G., Cachero, T. G., et al. (2005). Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201, 1375–1383. doi:10.1084/jem.20042309

Ishii, N., Takahashi, T., Soroosh, P., and Sugamura, K. (2010). OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv. Immunol. 105, 63–98. doi:10.1016/S0065-2776(10)00030-0

Ito, T., Wang, Y. H., Durdan, O., Hanabuchi, S., Peng, O. A., Gillert, M., et al. (2006). OX40 lig and shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 103, 13138–13143. doi:10.1073/pnas.0603107103

Jackson, T. R., Blader, I. J., Hammonds-Odie, L. P., Burga, C. R., Cooke, E., Hawkins, P. T., et al. (1996). Initiation and maintenance of NF-g-stimulated neurite outgrowth requires activation of a phospho-inositol 3-kinase. J. Cell Sci. 109(Pt 2), 289–300.

Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H., and Kwon, B. S. (1998). Human 4-IBB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem. Physiol. Res. Commun. 242, 613–620. doi:10.1016/s0006-291x(97)80164-0

Joselewicz, Z. S., Lu, L. F., and Rudensky, A. Y. (2012). Regulatory T cell: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564. doi:10.1146/annurev.immunol.25.021016.146123

Kawamata, S., Hori, T., Imura, A., Takaori-Kondo, A., and Uchiyama, T. (1998). Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2 and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 273, 5808–5814. doi:10.1074/jbc.273.10.5808

Khusiagura, G., Orliineck, J. R., and Chao, M. V. (1999). Association of the p75 neurotrophin receptor with TRAF6. J. Biol. Chem. 274, 2597–2600. doi:10.1074/jbc.274.5.2597

Kim, E. Y., Prietel, I. J., Teh, S. I., and Teh, H. S. (2006). TNF receptor type 2 (p75) functions as a cosimulator for antigen-driven T cell responses in vivo. J. Immunol. 176, 1026–1035.

Kim, E. Y., and Teh, H. S. (2001). TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167, 6812–6820.

Kim, E. Y., and Teh, H. S. (2004). Criti- cal role of TNF receptor type 2 (p75) as a costimulator for IL-2 induc- tion and T cell survival: a functional link to CD28. J. Immunol. 173, 4503–4509.

Kimberley, B. R., Van Bostelen, L., Cameron, K., Hardenberg, G., Mar- quartz, J. A., Hahne, M., et al. (2009). The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross- linking. J. Biol. Chem. 274, 1584–1595. doi:10.1074/jbc.m108.672123

Kumar, M., Makonchuk, D. Y., Li, H., Mittal, A., and Kumar, A. (2009). TNF-like weak inducer of apoptosis (TWEAK) activates proinflammary signaling pathways and gene expression through the acti- vation of TGF-beta-activated kinase 1. J. Immunol. 182, 2439–2449. doi:10.4049/jimmunol.1800335

Kussuru, R., Guo, X., Conchonaud, F., Hamon, Y., Hawchar, O., Bernard, A. M., et al. (2008). Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activa- tion. Nat. Cell Biol. 10, 538–547. doi:10.1038/ncomms1130

Lee, H. W., Nam, O. K., Park, S. J., and Kwon, B. S. (2003). 4-IBB enhances CD8+ T cell expansion by regulating cell cycle progres- sion through changes in expression of cyclins D and E and cyclin- dependent kinase inhibitor p27kip1. Eur. J. Immunol. 33, 2133–2141. doi:10.1002/eji.200233996

Lee, H. W., Park, S. J., Choi, B. K., Kim, H. H., Nam, O. K., and Kwon, B. S. (2002). 4-IBB promotes the survival of CD8+ T lymphocytes by increas- ing expression of Bel-2 and Bcl-1. J. Immunol. 169, 4882–4888.

Lee, S. H., Kim, E. J., Suk, K., Kim, I. S., and Lee, W. H. (2010). TL1A induces the expression of TGF-beta-inducible gene h3 (betaig-h3) through PKC, PI3K, and ERK in THP-1 cells. Cell. Immunol. 266, 61–66. doi:10.1016/j.cellimm.2010.08.013

Leibbrandt, A., and Penninger, J. M. (2008). RANK/RANKL: regu- lators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 1143, 123–150. doi:10.1196/annals.1443.016

Leonardi, A., Ellinger-Ziegelbauer, H., Franzoso, G., Brown, K., and Sieben- list, U. (2000). Physical and func- tional interaction of filamin (actin- binding protein-280) and tumor necrosis factor receptor-associated factor 2. J. Biol. Chem. 275, 271–278. doi:10.1074/jbc.275.1.271

Liu, Y., Xu, L., Opalka, N., Kap- pler, J., Sha, H. B., and Zhang, G. (2002). Crystal structure of sTALL-1 reveals a virus-like assem- bly of TNF family ligands. Cell 108, 383–394. doi:10.1016/s0092-8674(02)00631-1

Madireddi, S., Schabowsky, R. H., Sristavasta, A. K., Sharma, R. K., Yolcu, E. S., and Shirwan, H. (2012). SA-4-IBBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP+ T regulatory cells by production of IFN-gamma. PLoS ONE 7:e42459. doi:10.1371/journal.pone.0042459

Marchetti, L., Klein, M., Schlett, K., Pfeiffer, K., and Essel, U. L. (2004). Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate recep- tor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase- dependent NF-kappaB pathway. J. Biol. Chem. 279, 32869–32881. doi:10.1074/jbc.M311766200

Marsters, S. A., Ayres, T. M., Sku- batch, M. A., Batch, M. C. L., Rothe, M., and Ashkenazi, A. (1997). Her- pesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with mem- bers of the TNFR-associated factor

So and Croft
family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem. 272, 14029–14032. doi:10.1074/jbc.272.22.14029
Meylan, F., Richard, A. C., and Siegel, R. M. (2011). TLR4 and TRAM, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 244, 188–196. doi:10.1111/j.1600-065X.2011.01068.x
Moreau, J., Legouffe, E., Jourdan, E., Quittet, P., Renne, T., Lugagne, C., et al. (2004). BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148–3157. doi:10.1182/blood-2003-06-1984
Muller, N., Wysogol, A., Okkenhaug, K. (2013). Signaling by the Muller, N., Wyzgol, A., Munkel, W., Brenner, D. A., Naiki, T., M., Ricciardi-Castagnoli, F., Schreiber, T. H., Wolf, D., Tsai, M. S., Schreiber, T. H., Wolf, D., Tsai, M. S., and Farber, J. L. (1999). Tumor necrosis factor family member TALL-1. J. Exp. Med. 202, 797–809. doi:10.1084/jem.20010530
Novoyatleva, T., Diehl, F., Van Amerongen, G. M., Patra, C., Ferrazzi, F., Belardelli, F., Bruno, L., Hertweck, A., Finazzi, F., Belardelli, F., Bruno, L., Hertweck, A., Finazzi, F., Porquet, N., Poirier, A., Houle, F., Pin, M., Rogers, P. R., Salek-Ardakani, S., Song, J., Song, J., Salek-Ardakani, S., Rogers, P. R., Cheng, M., Van Parijs, L., and Croft, M. (2004). The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5, 150–158. doi:10.1038/ni1030
Pike, L. J., and Casey, L. (1996). Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains. J. Biol. Chem. 271, 26453–26455. doi:10.1074/jbc.271.43.26453
Pullen, S. S., Miller, H. G., Everdeen, D. S., Dang, T. T., Crute, J. J., and Dorken, B., J. L., Morio, T., Fu, S. M., Reddy, S. A., Huang, J. H., and Liao, W. S. (2000). Phosphatidylinositol 3-kinase and protein kinase C gamma 2. J. Biol. Chem. 275, 673–680. doi:10.1074/jbc.179.2.673
Rickert, R. C., Jellina, J., and Maletic, A. V. (2011). Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244, 115–133. doi:10.1111/j.1600-065X.2011.01067.x
So, T., Lee, S. W., and Croft, M. (2006). Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int. J. Hematol. 83, 1–11. doi:10.1533/ijh.05120
So, T., Lee, S. W., and Croft, M. (2007). Cutting edge: OX40 inhibits TGF-beta and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179, 1427–1430.
So, T., Lee, S. W., and Croft, M. (2006). Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int. J. Hematol. 83, 1–11. doi:10.1533/ijh.05120
So, T., Lee, S. W., and Croft, M. (2006). Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 19, 253–262. doi:10.1016/j.cytogfr.2008.04.003
Starck, L., Scholz, C., Dorken, B., and Daniel, P. T. (2005). Costimulation by CD40/CD40 ligand is a key post-activation events of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol. Rev. 244, 197–217. doi:10.1111/j.1600-065X.2011.01065.x
Stearke, L., Schulz, C., Dorken, B., and Daniel, P. T. (2005). Costimulation by CD40/CD40 ligand is a key post-activation events of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol. Rev. 244, 197–217. doi:10.1111/j.1600-065X.2011.01065.x
Steinberg, M. W., Cheung, T. C., and Ware, C. A. J. (2006). The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169–187. doi:10.1111/j.1600-065X.2011.01064.x
So, T., Soroosh, P., Eun, S. Y., Altman, A., and Croft, M. (2011b). Antigen-independent signalsome of CARMA1, PKCθ, and TNF receptor-associated factor 2 (TRAF2) determines NF-κB signaling in T cells. Proc. Natl. Acad. Sci. U.S.A. 108, 293–298. doi:10.1073/pnas.100785108
So, T., Lee, S. W., and Croft, M. (2006). Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int. J. Hematol. 83, 1–11. doi:10.1533/ijh.05120
So, T., Lee, S. W., and Croft, M. (2006). Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 19, 253–262. doi:10.1016/j.cytogfr.2008.04.003
Song, J., Song, J., Salek-Ardakani, S., Rogers, P. R., Cheng, M., Van Parijs, L., and Croft, M. (2004). The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5, 150–158. doi:10.1038/ni1030
Song, J., Lee, S. W., and Croft, M. (2005). Sustained survival from XOX40 costimulatory signals drives T cell clonal expansion. Immunity 22, 621–631. doi:10.1016/j.immuni.2005.03.012
So, T., Soroosh, P., Doherty, T. A., So, T., Mehta, A. K., Khorraram, N., Norris, P. S., et al. (2011). Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. J. Exp. Med. 208, 797–809. doi:10.1084/jem.20110562
Stone, G. W., Barree, S., Snarsky, V., Kee, K., Spina, C. A., Yu, X. F., et al. (2006). Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J. Virol. 80, 1762–1772. doi:10.1128/JVI.04762-17226-2006
Takano, R., Hisahara, S., Namikawa, K., Kiya, H., Okano, H., and Miura, M. (2000). Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms. J. Biol. Chem. 275, 16360–16365. doi:10.1074/jbc.M104191999
Vaillant, A. R., Mazzoni, L., Tudan, C., Boudreau, M., Kaplan, D. R., and Miller, F. D. (1999). Depolarization and neurotrophins converge on the phosphatidylinositols 3-kinase-Akt pathway to synchronically regulate neuronal survival. J. Cell Biol. 146, 955–966. doi:10.1083/jcb.146.5.955
Vidalain, P. O., Aouch, O., Servet-Delprat, C., Rabourdin-Combe, C., Gerlier, D., and Manie, S. (2000). CD40 signaling in human dendritic cells is initiated within membrane rafts. EMBO J. 19, 3304–3313. doi:10.1093/emboj/19.13.3304
Vilap, M., Charalampopoulos, I., Kenchapp, R. S., Simi, A., Karaca, E., Reversi, A., et al. (2009). Activation of the p75 neurotrophin receptor through conformational rearrangement of disulfide-linked receptor dimers. Neuron 62, 72–83. doi:10.1016/j.neuron.2009.02.020
Vinay, D. S., and Kwon, B. S. (2012). Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11, 1062–1070. doi:10.1158/1535-7163.MCT-11-0167
Viola, A., and Gupta, N. (2007). This article was submitted to Frontiers in Immunology. doi:10.3389/fimmu.2013.00139
Zhang, R., Xu, Y., Ekman, N., Wu, Z., Wu, J., Altaldo, K., et al. (2003a). Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphorylinaisotol 3-kinase to modulate the tumor necrosis factor-induced angiogenic pathway. J. Biol. Chem. 278, 51267–51276. doi:10.1074/jbc.M308678200
Zhang, Z., Jin, E., and Bothwell, A. L. (2003b). Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J. Immunol. 171, 3620–3626.
Zhou, Z., Song, X., Berezov, A., Zhang, G., Li, Y., Zhang, H., et al. (2008). Human glucocorticoid-induced TNFR receptor ligand regulates its signaling activity through multiple oligomerization states. Proc. Natl. Acad. Sci. U.S.A. 105, 5465–5470. doi:10.1073/pnas.0711350105
Zonca, M., Mancheno-Corvo, P., Delarosa, O., Manes, S., Buscher, D., Lombardo, E., et al. (2012). APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase. Tissue Eng. Part A 18, 852–859. doi:10.1089/ten.tea.2011.0316
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Received: 04 April 2013; paper pending publication: 06 May 2013; accepted: 25 May 2013; published online: 07 June 2013.
Citation: So T and Croft M (2013) Regulation of PI3K and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front. Immunol. 4:139. doi:10.3389/fimmu.2013.00139
This article was submitted to Frontiers in T Cell Biology, a specialty of Frontiers in Immunology.
Copyright © 2013 So and Croft. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.